Lymphoma Ostiraliya ya yi nasara wajen karɓar kyautar duniya daga AbbVie don gudanar da tambayoyi tare da Australiya da masana na duniya a lymphoma da cutar sankarar lymphocytic na kullum (CLL). Tambayoyin za su ba da rahoton sabon bayani game da gwaje-gwaje na asibiti na lymphoma / CLL da kuma nazarin daga ko'ina cikin duniya kuma an gabatar da su a yayin taron ASH. Za a raba waɗannan tambayoyin a ko'ina cikin duniya ta hanyar ƙungiyoyin bayar da shawarwari na haƙuri.
Lymphoma Ostiraliya ta gudanar da kusan tambayoyi 40 a cikin kwanaki 4 na taron kuma muna so mu mika godiya ta gaske daga al'ummar lymphoma / CLL ga duk wanda ya ba da lokacinsa, iliminsa da gwaninta tare da mu.
B-cell Lymphoma
Dr Laurie Sehn - ASH Lymphoma Sabuntawa.
Dr Laurie Sehn daga Cibiyar Ciwon daji ta British Columbia daga Vancouver, Kanada ita ce Shugabar hukumar ba da shawara ta likitanci na Ƙungiyar Lymphoma ta Duniya. Dokta Sehn ya tattauna wasu mahimman bayanai a cikin hanyoyin kwantar da hankali waɗanda aka gabatar yayin taron ASH don lymphoma. Waɗannan sun haɗa da Polatuzumab (maganin magungunan antibody) don yaɗa manyan ƙwayoyin lymphoma B-cell (DLBCL) da Mosunetuzumab - (bispecific antibody) da aka yi amfani da su don ƙwayoyin lymphomas na B-cell waɗanda ba Hodgkin ba.Dr.
A/Prof Chan Cheah, mai ba da shawara ga likitan hanta, Asibitin Sir Charles Gairdner, Hollywood Private Hospital & Blood Cancer Research WA, a Perth, Western Australia, sun tattauna gabatarwar fosta a ASH na gwajin da aka gudanar a Ostiraliya ta amfani da sabon ƙarni na Bruton's Tyrosine Kinase (BTK) mai hanawa da ake kira TG-1701 da aka yi amfani da shi a cikin marasa lafiya tare da sake dawowa / refractor B-cell malignancies. Ana ba da wannan maganin na baka azaman wakili guda ɗaya tare da umbralisib (PI3K inhibitor) da ubiltuximab (glycoengineered anti-CD20 monoclonal antibody).Dokta George Yana Biyi - Sabuntawar Lymphoma.
Dokta George Follows shine Jagorar Clinical Lymphoma/CLL don Cambridge kuma yana ɗaukar alƙawura da yawa ciki har da shugaban taron UK CLL. Dr Bibiyar ta tattauna sabuntawa don lymphoma waɗanda aka gabatar yayin taron sha'awar ASH. Waɗannan sun haɗa da gwaji na lokaci na ta amfani da sabon magani da ake kira Monunetuzumab wanda ke bispecific monoclonal antibody wanda ke hari CD3 da CD20 kuma ya haifar da amsa mai ɗorewa a cikin marasa lafiya tare da ƙwayoyin cuta na B-cell waɗanda ba Hodgkin ba, gami da marasa lafiya waɗanda suka sake dawowa daga CAR T. -maganin salula.
Dr Stephen Schuste - Mosunetuzumab yana haifar da cikakkiyar gafara ga marasa lafiya tare da lymphoma na B-cell wadanda ba Hodgkin ba.
Bispecific monoclonal antibody Mosunetuzumab, wanda ke hari CD3 da CD20, ya haifar da amsa mai ɗorewa a cikin marasa lafiya tare da B-cell non-Hodgkin lymphoma (NHL), har ma a cikin waɗanda ke da cutar da ta sake dawowa ko kuma ta koma ga mai karɓar antigen na chimeric (CAR) T- cell far. Dokta Schuste ya tattauna batun ci gaba na I / Ib binciken (GO29781; NCT02500407) na mosunetuzumab a cikin marasa lafiya tare da B-cell non-Hodgkin lymphoma (NHL), wadanda suka sake komawa / refractory (R / R) zuwa hanyoyin CAR-T ko ga wanda jinkiri a cikin ingantaccen magani ya ware wannan hanyar. Bayanan farko sun goyi bayan cewa mosunetzumab yana da kyakkyawan juriya da inganci mai dorewa a cikin R/R B-cell NHL da aka riga aka yi wa magani.
Dr John Leonard - karin bayanai daga taron na lymphoma.
Dokta Leonard ya tattauna ra'ayoyin ƙwararrunsa daga gabatarwar lymphoma yayin taron. Ya tattauna batutuwa da dama da suka haɗa da: • Lymphoma follicular - chemo free regimens • Yada manyan B-cell Lymphoma - lafiyar kashi a marasa lafiya bayan R-CHOP da CAR T-cell therapy • Mantle Cell Lymphoma - sababbin magunguna tare da chemotherapy • Gwajin jini na DNA • Alurar rigakafi na Lymphoma
Ciwon daji na Lymphocytic na yau da kullun (CLL) & Karamar cutar sankarar bargo ta Lymphocytic (SLL)
Dr Brian Koffman - Sabuntawar CLL & shawarwarin haƙuri.
Dokta Koffman, sanannen likita, malami da farfesa na asibiti ya juya CLL mai haƙuri, ya sadaukar da kansa ga koyarwa da kuma taimakawa al'ummar CLL tun lokacin da aka gano shi a 2005. Dokta Koffman ya yi imanin cewa matsayinsa na biyu a matsayin likita da mai haƙuri yana ba da wani abu na musamman. kwarewa da fahimta wanda ke ba shi damar ba da cikakkun bayanai game da batutuwa masu rikitarwa da kuma ba da shawara ga 'yan uwansa marasa lafiya da kuma sanar da abokan aikinsa na kiwon lafiya. Wannan yana da mahimmanci musamman idan aka yi la'akari da yanayin yanayin warkewa da sauri. Dr Koffman shi ne wanda ya kafa CLL Society, Amurka. Dokta Koffman ya tattauna abubuwan da aka sabunta na CLL daga taron ciki har da sabuntawa game da CAR T-cell far, ibrutinib, acalabrutinib, jerin magunguna da magungunan hade daban-daban. Ya kuma tattauna mafi kyawun gudanarwa na CLL, gami da gwajin kwayoyin halitta kafin magani da kuma waɗancan marasa lafiya da ke da cututtukan da ba su da ƙarfi, 17p del bai kamata su sami chemotherapy ba, maimakon maganin da aka yi niyya.
Farfesa John Gribben da Deborah Sims - Bayanin jiyya na CLL.
Farfesa Gribben ya tattauna ra'ayinsa game da sabuntawa daga taron inda yawancin abubuwan da aka gabatar sun karfafa cewa magungunan da ake amfani da su suna da kyau saboda an dade ana bin su. Tare da dogon bibiya kuma yana zuwa da sanin sabbin abubuwan guba waɗanda zasu iya bayyana. Za mu iya ilmantar da marasa lafiya da kyau tare da samun kyakkyawar fahimtar abin da za mu yi tsammani. Ya kuma tattauna sabbin hanyoyin kwantar da hankali na zamani waɗanda aka gabatar, ba kawai a cikin CLL ba, amma sauran lymphomas irin su Follicular lymphoma & Mantle cell lymphoma. Hakanan akwai gwaje-gwajen asibiti na farko da yawa tare da sabbin magunguna waɗanda ke nuna alkawari. Damuwa ta gaba ita ce tare da waɗannan sabbin hanyoyin kwantar da hankali da haɗin gwiwar hanyoyin kwantar da hankali, yana zuwa ƙarin kuɗi don tsarin kiwon lafiya.
Farfesa Stephan Stilgenbauer da Deborah Sims - Sabuntawa game da gudanar da CLL/SLL.
Farfesa Stilgenbauer ya ba da bayyani game da sabuntawar jiyya ga marasa lafiya tare da CLL/SLL daga taron ASH. Ya yi magana game da amfani da sababbin hanyoyin kwantar da hankali a matsayin wakilai guda ɗaya kuma a cikin haɗuwa da ke da sakamako mai mahimmanci ga marasa lafiya, musamman ma wadanda ba su da cutar da kuma saboda haka ba sa amsawa ga tsarin kulawa na gargajiya na chemotherapy. Jiyya na gaba don CLL/SLL na iya zama chemotherapy na iya zama magani na biyu ko na uku.
A/Prof Constantine Tam da Deborah Sims - CLL & Mantle Cell Lymphoma.
A/Prof Constantine Tam, Peter MacCallum Cancer Center, RMH & St Vincent's Hospital yayi magana da Deborah Sims, daga Lymphoma Australia. Dr Tam yana ba da fahimtarsa daga abubuwan da suka fi dacewa daga taron akan CLL da Mantle cell lymphoma. Ya ba da bayyani game da gabatarwar 3 da aka yaba sosai don cutar sankarar bargo ta Chronic Lymphocytic (CLL) & Small Lymphocytic Lymphoma (SLL).
Dokta George Yana Bi- Sabuntawar CLL.
Dokta George Follows daga Burtaniya ya tattauna da Lymphoma Australia a taron kungiyar American Society of Hematology (ASH) da aka gudanar kwanan nan a Orlando, Amurka. Dr Follows shine Jagorar Clinical Lymphoma/CLL don Cambridge kuma yana ɗaukar alƙawura da yawa ciki har da shugaban taron UK CLL. Ya tattauna sabuntawa game da sabon binciken da sakamakon binciken da aka gabatar a taron ASH akan CLL.
Dokta Nitin Jain da Deborah Sims - Ibrutinib & Venetoclax a cikin marasa lafiya tare da CLL.
Dokta Nitan Jain, Mataimakin Farfesa ne a Sashen Cutar sankarar jini a Jami'ar Texas MD Anderson Cancer Center a Houston, Texas, Amurka. Dokta Nitan ya tattauna abubuwan da ya gabatar na 2 a yayin taron ASH na nazarin 2 da aka gudanar a MD Anderson Cancer Center ta amfani da Ibrutinib da venetoclax tare da marasa lafiya tare da cutar sankarar lymphocytic na kullum (CLL) a duka jiyya na farko da kuma wadanda ke fama da cututtuka / refractory. Sakamako ya nuna cewa a cikin ƙungiyoyin biyu haɗin haɗin gwiwa ta amfani da ibrutinib da venetoclax shine ingantaccen tsarin maganin maganin chemotherapy ga marasa lafiya tare da CLL kuma za a ci gaba da ci gaba da karatu.
Dr Tanya Siddiqi – CAR T-cell a cikin CLL da aka sake dawowa/raba.
Dokta Tanya Siddiqi ita ce Darakta, Shirin Ciwon daji na Lymphocytic na Chronic, Cibiyar Toni Stephenson Lymphoma da A/Prof Department of Hematology & Hematopoietic Transplantation a Birnin Hope National Medical Center, Duarte, Amurka. Dokta Siddiqi ta tattauna batun gabatar da ita a lokacin taron na kashi na nazari don kula da marasa lafiya da suka sake komawa ko kuma masu fama da CLL. Duk marasa lafiya a baya sun karɓi aƙalla daidaitattun jiyya guda 3, gami da ibrutinib kuma rabin marasa lafiya suma sun sami venetoclax. Binciken ya kula da marasa lafiya 23 tare da CAR T-cell far inda sama da 80% sun sami amsoshi masu dorewa a cikin watanni 6. Ana ci gaba da bibiya.
Farfesa John Seymour - Bayanin binciken Murano - CLL/SLL.
Farfesa Seymour ya gabatar da bincike na shekaru hudu na binciken Murano wanda ya tabbatar da ci gaba da fa'ida ta iyakanceccen lokaci Venetoclax & rituximab a cikin sake dawowa ko cutar sankarar lymphocytic na yau da kullun (CLL). Venetoclax (Ven) babban zaɓi ne mai hana baki na maɓallin apoptosis mai sarrafa BCL-2, wanda aka wuce gona da iri a cikin CLL. MURANO (nazarin mataki na III bazuwar) idan aka kwatanta ƙayyadaddun lokaci VenR tare da daidaitaccen bendamustine-rituximab (BR) a cikin R/R CLL. An kafa mafi girman ci gaba ba tare da rayuwa ba (PFS) na VenR da BR a cikin bincike na farko da aka tsara (Seymour et al. N Engl J Med 2018); An ci gaba da samun fa'idar PFS tare da dogon bin diddigin kuma bayan duk marasa lafiya sun gama jiyya.
Farfesa Peter Hillmen - Kalubale a cikin yanayin jiyya na CLL/SLL.
Farfesa Hillman ya tattauna wasu ƙalubalen yanayin yanayin jiyya cikin sauri don CLL/SLL tare da yawancin hanyoyin kwantar da hankali akan kasuwa.
Farfesa Peter Hillmen - Sabuntawar CLL daga ASH 2019.
Farfesa Hillmen ya tattauna wasu mahimman bayanai daga taron game da gwaje-gwajen jiyya na novel da aka yi amfani da su a cikin saitin gaba wanda aka gabatar wanda ya nuna sakamako mai kyau tare da amfani da ibrutinib (BTK inhibitor), acalabrutinib (sabuwar BTK inhibitor), venetoclax (BCL2 inhibitor). ) da kuma amfani da hanyoyin kwantar da hankali. Ya kuma tattauna gwaje-gwaje na asibiti a cikin yanayin da aka sake dawowa yana nuna sakamako mai kyau wanda ya hada da CAR T-cell far. Godiya ga Kulawar cutar sankarar bargo don raba hirar da Lymphoma Ostiraliya.
Farfesa Miles Prince - Gwajin Halitta (CLL/SLL) & CAR T-cell far.
Farfesa Prince ya tattauna ra'ayoyinsa game da manyan batutuwan da ke da sha'awa ga lymphoma daga taron. Ya tattauna cewa hanya mafi kyau don magance cutar sankarau na majiyyaci, ana buƙatar fahimtar cutar su kuma a san su sosai. An nuna cewa marasa lafiya da aka gano tare da CLL / SLL suna buƙatar yin gwajin kwayoyin halitta kafin samun magani. Marasa lafiya waɗanda ba su canzawa da TP53 da aka canza CLL/SLL, an nuna chemotherapy ba zai yi tasiri ga wannan rukunin masu haƙuri ba. A cikin Amurka da Birtaniya (da wasu ƙasashen Turai) marasa lafiya suna ba da kuɗi don karɓar Ibrutinib gaba-gaba, duk da haka wannan ba haka bane a Ostiraliya, inda marasa lafiya ke karɓar chemo-immunotherapy da ibrutinib a cikin jiyya na biyu.
Yada Manyan B-cell Lymphoma (DLBCL)
A/Prof Chan Cheah – M Lymphoma, Yada Manyan B Cell lymphomas.
A/Prof Cheah ya sake yin bita ga takarda "Aggressive Lymphoma (Diffuse Large B-cell da sauran m b-cell non-Hodgkin lymphomas) - sakamakon gwajin gwaji na asibiti: inganta aikin chemotherapy na gaba" wanda aka gudanar a ranar Lahadi 8 ga Disamba a ASH 2019.
Dr Jason Westin – Yada Manyan B-cell Lymphoma updates & Smart Start Study.
Dokta Westin ya tattauna wasu abubuwan da suka fi dacewa daga taron a DLBCL ciki har da CAR T-cell far da sabuntawa daga binciken da ke amfani da ƙananan ƙwayoyin cuta kuma don haka inganta illa masu guba ga marasa lafiya.
Lymphoma na follicular
Dr Loretta Nastoupil - Nazarin lymphoma follicular - Part 1.
Dokta Nastoupil yana tattaunawa game da sakamakon binciken lokaci na II na Obintuzumab (nau'in anti-CD20 monoclonal antibody na II) da Lenalidamide (wakilin immunomodulatory) a baya wanda ba a kula da shi ba, babban nauyin FL. An ga wannan haɗin gwiwar hanyoyin kwantar da hankali da kyau da kuma tasiri a cikin binciken da aka yi a baya don marasa lafiya da aka bi da su a cikin sake dawowa ko FL.
Dr Loretta Nastoupil - Nazarin lymphoma follicular - Part 2.
Dokta Nastoupil ta tattauna sakamakon bincikenta na kashi na II na Obintuzumab (nau'in anti-CD20 monoclonal antibody na II) da Lenalidamide (wakilin immunomodulatory) a baya wanda ba a kula da shi ba, babban nauyin FL. Ƙarin nazarin wannan tasiri, tsarin maganin rigakafi a cikin FL mara lafiya yana da garanti. Dokta Nastoupil ya tattauna dalilan wannan tasiri mai tasiri da jurewa ga kowane yawan majiyyata da lymphoma Follicular.
A/Prof Chan Cheah - Sabunta gwajin asibiti na Follicular lymphoma.
Dr Cheah ya tattauna gabatar da Dr Loretta Nastoupil daga Cibiyar Ciwon daji na MD Anderson, Texas yayin taron ASH 2019. Nazarin kashi na II ya kalli maganin marasa lafiya Follicular lymphoma marasa lafiya a baya tare da Obintuzumab (nau'in anti-CD20 monoclonal antibody na II) da Lenalidamide (wakilin immunomodulatory), tare da babban nauyin ƙari. An ga wannan haɗin gwiwar hanyoyin kwantar da hankali da kyau da tasiri a cikin binciken da aka yi a baya don marasa lafiya da aka yi amfani da su a cikin FL da aka dawo da su ko kuma masu tayar da hankali da aka gudanar a Cibiyar Ciwon daji na MD Anderson ta Farfesa Nathan Fowler (nazarin RELEVANCE).
Dr Allison Barraclough -Nivolumab + Rituximab a cikin Layi na Farko na Lymphoma.
Dokta Barraclough ya tattauna sakamakon wucin gadi na farko a cikin nazarin lokaci na II na duniya, wanda Dr Eliza Hawkes ke jagoranta, kula da layin gaba na marasa lafiya tare da mataki na 1-3A follicular lymphoma. Nazarin yana amfani da hanyar haɗin gwiwar maganin rigakafi kawai, wanda kawai an gwada shi a baya a cikin koma baya. Marasa lafiya suna karɓar nivolumab kawai na makonni 8 na farko kuma idan sun sami cikakkiyar amsa, za su ci gaba da nivolumab wakili ɗaya. Ga waɗanda kawai suka sami amsa na ɓangarori za su ci gaba da samun haɗuwa akan nivolumab da rituximab. Sakamako sun yi kyau tare da ƙimar amsa gabaɗaya (ORR) na 80% kuma sama da rabin waɗannan marasa lafiya sun sami cikakkiyar amsa (CR). Akwai ƙananan bayanan guba, inda yawancin marasa lafiya har yanzu suna iya yin aiki da ci gaba da ayyukan rayuwa na yau da kullun
Lymphoma na Mantle Cell
Dr Sasanka Handunetti - Mantle Cell Lymphoma (Sabuntawa na binciken AIM).
Dokta Handunetti ya tattauna batun gabatar da ita game da sabuntawar shekaru uku na binciken lokaci na II AIM (TAM, et al, NEJM 2018) da aka gudanar a Cibiyar Ciwon daji ta Peter MacCallum a Melbourne, ta amfani da haɗin gwiwar BTK mai hanawa ibrutinib da BCL-2 inhibitor venetoclax far a cikin marasa lafiya tare da matalauta tsinkaya mantle cell lymphoma (MCL). Sakamakon ya nuna matsakaicin ci gaba kyauta na watanni 29. Ya tayar da tambayar cewa akwai yuwuwar ƙayyadadden lokaci da aka yi niyya-maganin jiyya a cikin gudanarwa na sake dawowa ko MCL.
Farfesa Steven Le Gouill - Nazarin Mantle Cell Lymphoma.
Farfesa Le Gouill ya tattauna karatunsa na I don sabon MCL da aka gano ta hanyar amfani da Ibrutinib, Venetoclax da Obintuzumab waɗanda duk an nuna su a baya suna da tasiri a cikin yanayin da aka sake dawowa / refractory a matsayin wakilai guda ɗaya kuma a hade a cikin sake dawowa / refractory (R / R) MCL. . Har ila yau, ya ba da wani bayyani na ma'auni na kulawa ga marasa lafiya tare da MCL ga ƙananan marasa lafiya da tsofaffi a cikin layi na gaba da R / R.
Farfesa Simon Rule – Mantle Cell Lymphoma Update.
Farfesa Simon Rule ya tattauna batun gabatar da hotonsa a taron yana duban shekaru 7.5 na bin marasa lafiya tare da sake dawowa ko MCL marasa lafiya wanda ke kan ibrutinib (BTK inhibitor) wanda ya nuna adadin marasa lafiya har yanzu suna cikin gafara fiye da shekaru 5. Hakanan ya nuna cewa marasa lafiya waɗanda suka karɓi Ibrutinib a cikin layin farko na jiyya sun sami amsa mai ɗorewa, fiye da waɗanda suka karɓi lattique.
KTE-X19: Zaɓin T-Cell na Mota don Lymphoma na Mantle?
Kashi casa'in da uku cikin dari na marasa lafiya tare da relapsed / refractory mantle cell lymphoma (MCL) sun amsa magani tare da KTE-X19, wani autologous anti-CD19 chimeric antigen receptor (CAR) T-cell far, bisa ga sakamakon daga gwajin ZUMA-2 da aka gabatar. a taron shekara-shekara na ASH na 2019.
Hodgkin Lymphoma
Dr Jessica Hochberg - Chemotherapy, Matasa Manya & Hodgkin Lymphoma.
Adadin warkewa ga sabon kamuwa da cutar Hodgkin Lymphoma yana da yawa tare da haɗin gwiwar yin amfani da chemoradiotherapy. Duk da haka, wannan sau da yawa yana haifar da mummunan aiki na jiki da na kwakwalwa wanda zai iya tasiri sosai ga ingancin rayuwa a tsakanin masu tsira. Bugu da ƙari na Brentuximab vedotin da Rituximab zuwa haɗakar haɗarin da aka daidaita chemotherapy (ba tare da cyclophosphamide, etoposide ko bleomycin ba) don sabon kamuwa da cutar Hodgkin Lymphoma ya bayyana yana da aminci ga yara, matasa da matasa. Sakamakonmu yana nuna gagarumin alƙawari tare da ƙimar CR na 100%, 58% saurin amsawa da wuri da raguwa mai mahimmanci a cikin amfani da chemotherapy mai guba da radiation. EFS/OS har zuwa yau shine 100% tare da tsaka-tsakin lokaci mai biyo baya fiye da shekaru 3.5.
Farfesa Andrew Evens - Nazarin kasa da kasa na Hodgkin Lymphoma.
Farfesa Evens memba ne mai aiki na HOLISTIC (Nazarin Kasa da Kasa na Hodgkin Lymphoma don Kula da Mutum) - ƙungiyar ƙasa da ƙasa tana haɗa ƙungiyar ƙwararrun masana daban-daban daga ko'ina cikin duniya don yin nazarin ƙwararrun ɓangarorin Hodgkin lymphoma prognosis, annoba, jiyya, tsira da sakamakon lafiya. a duk kungiyoyin shekaru. Suna daidaita bayanan mutum ɗaya daga gwaje-gwajen asibiti sama da 20 na zamani daga Arewacin Amurka da Turai na kowane zamani da kuma cibiyoyin rajista na 6 da na yanki na Hodgkin lymphoma, da kuma babban aikin likitancin al'umma. Manufar su ita ce haɓaka yanke shawara ga yara da manya Hodgkin lymphoma marasa lafiya da masu bayarwa, da aka ba da zaɓuɓɓukan jiyya na faɗaɗa kuma idan babu cikakkun bayanai masu mahimmanci da na dogon lokaci.
Dr Stephen Ansell da Deborah Sims - Hodgkin Lymphoma.
Dokta Ansell babban kwararre ne a cikin lymphoma ba Hodgkin da lymphoma na Hodgkin a Mayo Clinic, Amurka. Dokta Ansell ya yi magana game da lymphoma na Hodgkin - zaman jiyya na gaba a ASH wanda ya halarta. Zaman ya ba da haske game da gwajin asibiti wanda aka ƙara amfani da shi a cikin sabbin hanyoyin kwantar da hankali a cikin saitin layi na gaba, ta yadda ƙara Brentuximab Vedotin & mai hana PD-1 da rage wasu ma'auni na chemotherapy wanda shine bleomycin, ya nuna sakamako mai ban mamaki. Sakamakon ya kuma rage yawan guba ga marasa lafiya da ke karɓar wannan magani idan aka kwatanta da daidaitattun jiyya. Daidaitaccen jiyya a cikin lymphoma na Hodgkin yana da sama da duk ƙimar amsawa inda kusan kashi 90% na marasa lafiya suka kai cikakkiyar amsawar rayuwa. Yawancin gwaje-gwaje a cikin lymphoma na Hodgkin a halin yanzu an yi niyya don rage bayanin mai guba da kuma ƙarshen tasirin waɗannan marasa lafiya.
Ƙwararren yanki na Lymphoma
Dokta Sasanka Handunetti - Nazari na Mataki na II a cikin Maimaituwa ko Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙwara.
Dokta Handunetti ya tattauna wani gabatarwar takarda daga ƙungiyar a Cibiyar Ciwon daji ta Peter MacCallum yayin taron yin amfani da ibrutinib a hade tare da venetoclax ga marasa lafiya tare da relapsed ko refractory Marginal Zone Lymphoma (MZL). MZL cuta ce da ba za ta iya warkewa ba wanda babu daidaitattun jiyya a cikin koma baya ko saiti. Duk waɗannan magunguna an ga su suna da shaidar aiki da kuma jurewa a matsayin masu zaman kansu (ma'aikata guda ɗaya) kuma wannan binciken ya yi nufin kimanta amsa a matsayin haɗin gwiwa.
Tsarin Jijiya ta Tsakiya Lymphoma
Dr Katherine Lewis – Tsarin Jijiya na Farko na Farko (PCNSL).
Dokta Lewis ya tattauna gabatarwar fosta a ASH 2019 wanda ya kalli sakamakon ga marasa lafiya da tsarin kulawa na farko ko na biyu (kwakwalwa da kashin baya) lymphoma da aka yi wa Ibrutinib (BTK inhibitor). Wannan ƙwayar lymphoma ce mai wuya kuma mai tsanani inda wannan rukunin marasa lafiya ba su da tsinkaya mara kyau tare da sau da yawa ana bi da su tare da tsarin haɗin gwiwar chemotherapy. Wannan wani bincike ne na baya-bayan nan wanda ya tattara bayanai daga ko'ina cikin Ostiraliya da New Zealand na marasa lafiya 16 waɗanda aka bi da su tare da Ibrutinib monotherapy a cikin sake dawowa / sake dawowa. Kodayake ƙananan adadin marasa lafiya, sakamakon ya kasance mai ban sha'awa, tare da ƙimar amsawa har zuwa 81%.
Waldenstrom ta Macroglobulinemia
Farfesa Mathias Rummel - Waldenstrom's Macroglobulinemia & gwajin StiL.
Ya rufe sakamakon shekaru 2 bayan binciken StiL yana kallon kulawar Rituximab vs observation post bendamustine-rituximab. Sakamako ya nuna cewa kulawar rituximab baya inganta rayuwa gabaɗaya. Farfesa Rummel ya kuma bayar da bayyani kan yadda ake gudanar da WM a halin yanzu.
T-cell Lymphoma
Na gefe T-cell Lymphoma
Dr Jasmine Zain, MD - ta tattauna mafi kyawun karatu a cikin PTCL da aka gabatar a ASH 2019.
(Godiya ga OBRoncology).
Dokta Zain, Daraktan Shirin T-cell Lymphoma, Sashen Nazarin Halittar Jiki da Ciwon Jiki, Cibiyar Toni Stephenson Lymphoma, City of Hope, ya tattauna mafi ban sha'awa nazarin da aka yi a cikin maganin lymphoma na T-cell lymphoma (PTCL) da aka gabatar a ASH. 2019.
Dokta Jasmine Zain - Yadda jiyya ga ƙwayoyin lymphoma na T-cell ya samo asali.
(Godiya ga OBRoncology).
Dokta Zain, Daraktan Tsarin T-cell Lymphoma, Sashen Nazarin Halittar Jiki da Ciwon Jiki na Hematopoietic, Cibiyar Toni Stephenson Lymphoma, Birnin Bege, yayi la'akari da yadda magungunan T-cell lymphoma (PCL) ya samo asali a cikin 'yan shekarun nan.
Dr Jasmine Zain – Novel hanyoyin magance PTCL gami da CAR T-cell far.
(Godiya ga OBRoncology).
Dokta Zain, Daraktan Tsarin T-cell Lymphoma, Sashen Nazarin Halittar Jiki da Ciwon Jiki, Cibiyar Lymphoma ta Toni Stephenson, Birnin Hope, ya gaya mana game da wasu hanyoyin da aka saba da su a cikin ci gaba don maganin ƙwayoyin lymphoma na T-cell. PTCL).
Dokta Timothy Illidge, ya bayyana makasudin kaiwa PTCL hari.
(Godiya ga OBRoncology).
Dr. Elisha, Farfesa daga Magungunan Tard da Orcology, Rigina na Ka'idodin Kimiyya, Jami'ar Christer, ta yi bayanin manufar niyya ta kashi-endmphoma (PTCL).
